The Department of Health and Social Care (DHSC) has today (28/08/2025) confirmed the following list of price concessions for August 2025: Drug Pack size Price concession Acetazolamide 250mg tablets 112 £51.02 Amiodarone 100mg tablets 28 £2.24 Amiodarone 200mg tablets 28 £4.82 Buprenorphine 2mg sublingual tablets sugar free 7 £1.83 Carbocisteine 250mg/5ml oral solution 300 £4.99 Co-amoxiclav
Read moreThe Department of Health and Social Care (DHSC) has today (27/08/2025) confirmed the following list of price concessions for August 2025: Drug Pack size Price concession Betamethasone 500microgram soluble tablets sugar free 100 £31.95 Bumetanide 1mg tablets 28 £2.94 Buprenorphine 8mg sublingual tablets sugar free 7 £6.00 Co-codamol 30mg/500mg effervescent tablets 32 £2.40 Co-codamol 30mg/500mg effervescent
Read more“While implementation of the 2025/26 CPCF continues at pace, our sights are also set on the future,” writes Community Pharmacy England Chief Executive Janet Morrison in a new blog. Despite the funding uplift earlier this year, pharmacy businesses remain in a financially precarious position. Janet explains that the views of pharmacy owners and their experiences
Read moreBy Chief Executive Janet Morrison As the summer draws to a close, everyone in community pharmacy and the wider health service will be preparing, or perhaps more aptly bracing, themselves for what will undoubtedly be another frantic autumn and winter period. For community pharmacy, the announcement of the Community Pharmacy Contractual Framework (CPCF) arrangements for
Read moreFollowing a decision taken by Eli Lilly to increase its UK list prices for Mounjaro® (Tirzepatide) KwikPen® from 1 September 2025, the Department of Health and Social Care (DHSC) has re-determined the NHS reimbursement prices for all strengths of Mounjaro® dispensed from September to reflect the new, higher list prices. To avoid pharmacy owners dispensing
Read moreDapagliflozin 5mg and 10mg tablets reimbursement prices have decreased following a move from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. More information on the
Read moreThe Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 September 2025. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item requiring reconstitution
Read moreCommunity Pharmacy England has today released a national report highlighting how pharmacy owners across England are dipping into personal savings to support their businesses, effectively subsidising the provision of NHS services. The Pharmacy Pressures Survey 2025: Funding and Profitability Report sets out once again the desperate financial position community pharmacies are in as a result of
Read moreThe Department of Health and Social Care (DHSC) has issued a medicine supply notification for the following product: Repaglinide 500microgram,1mg and 2mg tablets MSN/2025/050 Tier 2 – medium impact Date of issue: 26/08/2025 Repaglinide 500microgram and 1mg tablets will be out of stock from late August until early December 2025 Repaglinide 2mg tablets are in
Read moreMHRA Class 4 Medicines Notification: Various Products (Ipca Laboratories UK Limited) Date issued: 26 August 2025 Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information. DMRC reference number: DMRC-35766519 Marketing Authorisation Holder: Ipca Laboratories UK
Read more
